Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619001597189
Ethics application status
Approved
Date submitted
4/09/2019
Date registered
20/11/2019
Date last updated
12/04/2023
Date data sharing statement initially provided
20/11/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
Joint UK and Australia multicentre, randomised, double blind, placebo controlled pragmatic trial comparing 52 weeks of azithromycin to placebo in children with neurological impairment at risk of lower respiratory tract infection (the PARROT trial).
Query!
Scientific title
The effect of prophylactic antibiotics on chest infections in children with neurological impairment (Parrot) trial.
Query!
Secondary ID [1]
299072
0
Sponsor (UK): UoL001460
Query!
Secondary ID [2]
299073
0
NIHR HTA (UK): 16/17/01
National Health and Medical Research Council (Australia): 1157228, APP1149332
Query!
Secondary ID [3]
299074
0
ISRCTN71955516
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PARROT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Neurological impairment
314260
0
Query!
Lower respiratory tract infection
314261
0
Query!
Condition category
Condition code
Neurological
312615
312615
0
0
Query!
Other neurological disorders
Query!
Respiratory
312636
312636
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Arm 1: Azithromycin
The dosing regimen is based on body weight (10mg/kg rounded) and will be administered as an oral suspension 3 times weekly (Mon/Wed/Fri) for 52 weeks.
Adherence will be monitored at 13, 26, 39 and 52 weeks using an IMP treatment diary and withdrawals from study treatment will also be monitored.
Query!
Intervention code [1]
315465
0
Treatment: Drugs
Query!
Comparator / control treatment
Arm 2: Placebo
Placebo matching azithromycin will be supplied as powder for oral suspension.
For both UK and Australia, inert, matched excipients are used.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
321268
0
Proportion of children hospitalised* with Lower Respiratory Tract Infection (LRTI) over the 52-week intervention period.
Parents will be asked at the timepoints specified below if they have attended hospital due to a LRTI. The research team will review any admissions to the recruiting centre against the LRTI criteria specified in the protocol and document on the applicable CRF. Parents will be asked and patients hospital records will be checked as part of the follow-up visit.
*Hospitalisation includes those who are admitted to hospital for only a short period with LRTI e.g. 12 hours and go home with a course of antibiotics. However, if participants are hospitalised again within 2 weeks of the initial admission, this will be classified as the same event.
Query!
Assessment method [1]
321268
0
Query!
Timepoint [1]
321268
0
At 4, 8, 13, 17, 21, 26, 30, 34, 39, 43, 47 and 52 weeks:
Hospitalisations due to LRTI.
Primary outcome assessment will be at 52 weeks.
Query!
Secondary outcome [1]
374491
0
Change in health related QoL of parent / carer (composite outcome).
Query!
Assessment method [1]
374491
0
Query!
Timepoint [1]
374491
0
At baseline, 13, 26, 39, 52 weeks
• Parent QoL assessment (Warwick-Edinburgh)
• Patient QoL assessment (DISABKIDS)
Query!
Secondary outcome [2]
374492
0
Safety events
Query!
Assessment method [2]
374492
0
Query!
Timepoint [2]
374492
0
At 4, 13, 17, 21, 26, 30, 34, 39, 43, 47 and 52 weeks:
• Assessment of adverse reactions
Known adverse reactions include mild diarrhoea, stomach pains, nausea or vomiting, headache and dizziness. There is also a small chance that azithromycin may cause a rash, or hearing problems.
Participants will attend face-to-face visits and scheduled phone/email contact will be made. Any data related to adverse reactions will be collected at these timepoints and recorded on the CRFs. PIs and delegated investigators are responsible for reporting all adverse reactions via the adverse event CRF within 7 days of becoming aware of the event and are responsible for reporting serious adverse reactions via the serious adverse reaction CRF within 24 hours of becoming aware of the event.
Query!
Secondary outcome [3]
374493
0
Changes in respiratory medication usage (composite outcome).
Parent will be asked about changes to respiratory medication and patient medical notes can also be used (not using data linkage).
Query!
Assessment method [3]
374493
0
Query!
Timepoint [3]
374493
0
At baseline, 4, 8, 13, 17, 21, 26, 30, 34, 39, 43, 47 and 52 weeks:
• Review of concomitant medication which could impact the respiratory system
At baseline and 52 weeks:
• Vaccinations
Query!
Secondary outcome [4]
374494
0
Changes in weight based on World Health Organisation z-scores using WHO Anthro (3.2.2) calculator (https://www.who.int/growthref/tools/en/). Weight will be measured in accordance with local standard practice.
Query!
Assessment method [4]
374494
0
Query!
Timepoint [4]
374494
0
At baseline, 13, 26, 39, 52 and 78 weeks:
• Weight
Query!
Secondary outcome [5]
374495
0
Change in quality / amount of parent's sleep.
(Composite outcome).
Query!
Assessment method [5]
374495
0
Query!
Timepoint [5]
374495
0
At baseline and 52 weeks:
• Primary caregiver sleep actigraphy and corresponding primary caregiver sleep log (UK only)
Query!
Secondary outcome [6]
374496
0
Change in respiratory symptoms assessed (composite outcome).
Respiratory symptoms will be assessed using methods specified below. Symptoms assessed by the questionnaires include:- Cough, wheeze, shortness of breath, ‘rattly’ chest, snoring, noisy breathing not from chest, noisy breathing from throat, fast breathing, feeding, activity levels, sleep disturbance, fatigue. Also the effect on family activities, adjustment to family life, disturbed sleep, worry / anxiety will be assessed.
Query!
Assessment method [6]
374496
0
Query!
Timepoint [6]
374496
0
At / baseline, 13, 26, 39, 52 and 78*weeks:
• LRSQ-Neuro score
• Respiratory symptom questionnaire
At 13, 26, 39, 52 and 78* weeks:
• Changes to respiratory treatments / support
• Surgical and other interventions
*assessment will only take place at 78 weeks if recruitment is still ongoing
Parent will be asked about changes to respiratory treatments/support, surgical and other interventions. Medical notes would also be reviewed (no data linkage).
Query!
Secondary outcome [7]
374497
0
Number, duration and severity of LRTI; time to first LRTI (composite outcome)
Query!
Assessment method [7]
374497
0
Query!
Timepoint [7]
374497
0
At 4, 8, 13, 17, 21, 26, 30, 34, 39, 43, 47 and 52 weeks:
• Attendance at Hospital, GP and number of days unwell with LRTI
• Changes to respiratory treatments / support
• Assessment of adverse reactions
Parent will be asked about attendance at hospital, GP and number of days unwell with LRTI, changes to respiratory treatments/support and whether they have/are experiencing any adverse reactions. Patient records will also be checked for hospital admissions.
Query!
Secondary outcome [8]
374498
0
Unscheduled medical presentations (GP visits and A&E attendances) for LRTI
Note: The LRTI definition at GPs will vary to the primary endpoint definition of LRTI
Query!
Assessment method [8]
374498
0
Query!
Timepoint [8]
374498
0
At baseline weeks:
• Medical history review
At 4, 8, 13, 17, 21, 26, 30, 34, 39, 43, 47 and 52 weeks:
• Attendance at Hospital and GP for LRTI
• Assessment of adverse reactions
Parent will be asked about medical history, attendance at hospital, GP and number of days unwell with LRTI and whether they have/are experiencing any adverse reactions. Patient records will also be checked for hospital admissions.
Query!
Secondary outcome [9]
374499
0
Use of other health and social care services, school attendance and indirect costs (composite outcome)
Query!
Assessment method [9]
374499
0
Query!
Timepoint [9]
374499
0
At baseline, 13, 26, 39, 52 and 78* weeks:
• Resource use questionnaire (Study-specific).
For participants that attend English centres at 52 and 78* weeks:
• Hospital Episode Statistics (HES)
*assessment at 78 weeks will only take place if recruitment to the trial is still ongoing
Query!
Secondary outcome [10]
374500
0
Number of courses of ‘rescue’ antibiotics prescribed for LRTI
Query!
Assessment method [10]
374500
0
Query!
Timepoint [10]
374500
0
At baseline, 4, 8, 13, 17, 21, 26, 30, 34, 39, 43, 47 52 and 78* weeks:
• Review of concomitant medications which could impact the respiratory system
Parent will be asked about respiratory medication usage. Medical records will also be reviewed.
*assessment at 78 weeks will only take place if recruitment to the trial is still ongoing
Query!
Secondary outcome [11]
374501
0
Quality-adjusted life years (QALY) assessment (composite outcome).
Query!
Assessment method [11]
374501
0
Query!
Timepoint [11]
374501
0
At baseline, 13, 26, 39, 52 and 78* weeks:
• CHU9D and EQ-5D-Y
CHU9D and EQ-5D-Y are used to evaluate the outcome measure ‘’Quality-adjusted life years (QALY) assessment.’’
*assessment at 78 weeks will only take place if recruitment to the trial is still ongoing
Query!
Secondary outcome [12]
374502
0
Nasal swab microbiology and resistance profiling; viral and bacterial causes of acute LRTI requiring hospitalisation (composite outcome)
Query!
Assessment method [12]
374502
0
Query!
Timepoint [12]
374502
0
At baseline, 26, 52 and 78* weeks:
• Nasal swab
*assessment at 78 weeks will only take place if recruitment to the trial is still ongoing
Query!
Secondary outcome [13]
374503
0
Nasal swab/nasopharyngeal aspirate to investigate viral causes of acute LRTI
Query!
Assessment method [13]
374503
0
Query!
Timepoint [13]
374503
0
When / if children are hospitalised with acute LRTI
Query!
Secondary outcome [14]
374504
0
Cough swab/sputum collection to investigate bacterial causes of acute LRTI
Query!
Assessment method [14]
374504
0
Query!
Timepoint [14]
374504
0
When / if children are hospitalised with acute LRTI
Query!
Secondary outcome [15]
375400
0
Change in health related QoL of child and parent/carer (composite outcome)
Query!
Assessment method [15]
375400
0
Query!
Timepoint [15]
375400
0
At baseline, 13, 26, 39, 52 weeks
• Parent QoL assessment (Warwick-Edinburgh)
• Patient QoL assessment (DISABKIDS)
Parent QoL assessment (Warwick-Edinburgh Mental Wellbeing Scale) and Patient QoL assessment (DISABKIDS) are used to evaluate the outcome measure ‘’Change in health related QoL of child and parent / carer’’(composite outcome).
Query!
Secondary outcome [16]
375401
0
Tolerability
Query!
Assessment method [16]
375401
0
Query!
Timepoint [16]
375401
0
At 4, 13, 17, 21, 26, 30, 34, 39, 43, 47 and 52 weeks:
• Assessment of adverse reactions
Parents will be asked if there have been any adverse events and an assessment of adverse reactions will be made by site.
At 13, 26, 39 and 52 weeks:
• Withdrawals from study treatment
Query!
Secondary outcome [17]
375402
0
Adherence to study medication.
Query!
Assessment method [17]
375402
0
Query!
Timepoint [17]
375402
0
At 13, 26, 39 and 52 weeks:
• IMP treatment diary
• Withdrawals from study treatment
Query!
Secondary outcome [18]
375403
0
Change in quality / amount of child / young person’s sleep (composite outcome).
Query!
Assessment method [18]
375403
0
Query!
Timepoint [18]
375403
0
At baseline and 52 weeks:
• Child’s Sleep Habits Questionnaire
• 1 week patient sleep diary
Query!
Eligibility
Key inclusion criteria
1. Children and young people who are aged between 3-17 years (inclusive) at randomisation
2. Written informed consent from participant (or appropriate person if incapacitated / minor)
3. Participant (or appropriate person if incapacitated / underage) and caregiver have a good understanding of the English language
4. Diagnosed with non-progressive, non-neuromuscular NI
5. Persistent respiratory symptoms*
6. One or more of the following:
a) Received at least 2 courses of oral antibiotics for LRTI in 52 weeks prior to eligibility
b) Have been hospitalised with a LRTI within 52 weeks prior to eligibility and completed 13 week ‘washout’ period (where applicable)**
c) Prescribed prophylactic antibiotics for LRTIs and undergone a 13 week ‘washout’ period**.
* Defined by: LRSQ-Neuro score of equal to or higher than 95%CI for age:
Age (in years) LRSQ-Neuro total score
greater than or equal to 3 and less than 6 greater than or equal to 11
greater than or equal to 6 and less than 11 greater than or equal to 5
greater than or equal to 11 and less than or equal to 17 greater than or equal to4
**Must have undergone a 13 week ‘washout’ period where administered IV antibiotics during hospitalisation or have been previously prescribed and administered prophylactic antibiotics.
Query!
Minimum age
3
Years
Query!
Query!
Maximum age
17
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Any neuromuscular disorders including SMA, Duchenne muscular dystrophy etc., or neurological disorders in which progressive deterioration in neurological condition are known to occur (e.g. Rett syndrome, some neurometabolic syndromes)
2. Pre-existing non-neurological conditions that impact on respiratory function such as cystic fibrosis (CF), immunodeficiency etc.
Note: Children with NI known to have bronchiectasis will not be excluded.
3. Known contra-indication to using (e.g. prolonged QT syndrome) or hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic or to any of the excipients contained in the study drug
4. Use of macrolide antibiotics within 90 days prior to eligibility
5. Known significant hepatic disease (hepatic impairment per Child-Pugh classification C)
6. Treatment with ergot derivatives (dihydroergocristine, dihydroergotamine, dihydroergotoxine, nicergoline or a combination of dihydroergocryptine with caffeine)
7. Child/young person already taking prophylactic antibiotics for non-respiratory causes (e.g. UTIs).
8. Previously randomised in PARROT
9. Recruited to another IMP trial and continuing to administer the IMP.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Parrot is a double-blind trial so the research / treating clinical team will be blinded to treatment allocation. There will be a designated unblinding team (usually pharmacy) at each centre who will be unblinded to treatment allocations. Randomisation will occur via a randomisation system and there will be back-up randomisation envelopes. Only the unblinded team will receive information regarding the unblinded treatment allocation.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation lists will be generated using block randomisation with random variable block length, stratified by site.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
To detect a 30% reduction in hospitalisation rate in children with NI and respiratory symptoms at risk of LRTI, with 90% power (alpha 0.05), we would require 225 patients per group, increasing to 250 allowing for 10% loss to follow-up/attrition, i.e. 500 children in total.
A Statistical Analysis Plan (SAP) will be developed for use in the interim and final analyses of the trial.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
22/06/2020
Query!
Actual
28/07/2020
Query!
Date of last participant enrolment
Anticipated
24/04/2023
Query!
Actual
Query!
Date of last data collection
Anticipated
31/08/2023
Query!
Actual
Query!
Sample size
Target
500
Query!
Accrual to date
85
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NT,QLD,VIC
Query!
Recruitment hospital [1]
14712
0
Queensland Children's Hospital - South Brisbane
Query!
Recruitment hospital [2]
14713
0
The Royal Childrens Hospital - Parkville
Query!
Recruitment hospital [3]
14720
0
Royal Darwin Hospital - Tiwi
Query!
Recruitment postcode(s) [1]
27752
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [2]
27753
0
3052 - Parkville
Query!
Recruitment postcode(s) [3]
27760
0
0810 - Tiwi
Query!
Recruitment outside Australia
Country [1]
21831
0
United Kingdom
Query!
State/province [1]
21831
0
Query!
Funding & Sponsors
Funding source category [1]
303607
0
Government body
Query!
Name [1]
303607
0
National Institute of Health Research Technology Assessment Programme (UK)
Query!
Address [1]
303607
0
Evaluation, Trials and Studies Coordinating Centre
University of Southampton
Alpha House
Enterprise Road
Southampton
SO16 7NS
Query!
Country [1]
303607
0
United Kingdom
Query!
Funding source category [2]
303714
0
Government body
Query!
Name [2]
303714
0
National Health and Medical Research Council (Australia)
Query!
Address [2]
303714
0
GPO Box 1421
Canberra ACT 2601
16 Marcus Clarke Street
Canberra City ACT 2600
Query!
Country [2]
303714
0
Australia
Query!
Primary sponsor type
University
Query!
Name
University of Liverpool
Query!
Address
2nd Floor Block D, Waterhouse Building,
3 Brownlow Street,
Liverpool,
L69 3GL
Query!
Country
United Kingdom
Query!
Secondary sponsor category [1]
303698
0
University
Query!
Name [1]
303698
0
Menzies School of Health Research
Query!
Address [1]
303698
0
John Mathews Building (Building 58)
Royal Darwin Hospital Campus
Rocklands Drive
Casuarina NT 0810
Query!
Country [1]
303698
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
304136
0
Children’s Health Queensland Hospital and Health Service Human Research Ethics Committee
Query!
Ethics committee address [1]
304136
0
Level 7, Centre for Children’s Health Research Queensland Children’s Hospital Precinct 62 Graham Street, South Brisbane QLD 4101
Query!
Ethics committee country [1]
304136
0
Australia
Query!
Date submitted for ethics approval [1]
304136
0
Query!
Approval date [1]
304136
0
06/08/2019
Query!
Ethics approval number [1]
304136
0
HREC/19/QCHQ/56353
Query!
Summary
Brief summary
Neurological Impairment (NI) in children is often caused by conditions such as cerebral palsy. Many children with NI are prone to chest infections which can lead to long stays in hospital, additional impairment and even premature death. Despite the suffering caused to children and their families by these infections and the high cost to health services, there is very little information on how best to prevent them. Some doctors prescribe long-term antibiotics but we don't really know whether this treatment makes any difference to the numbers of chest infections children suffer from, or whether these antibiotics can cause long term harm.
The trial is looking to recruit for 500 children and young people aged 3-17 years, with NI who are at risk of chest infections, along with their parents / primary care giver to take part. Children included in the trial will be given either azithromycin or a placebo for 12 months to compare the difference.
The trial is taking place in the UK and Australia and each participant will be involved for a maximum of 18 months. The aim of the trial is to find out whether 12-month's treatment with the antibiotic azithromycin reduces how often children with NI have to stay in hospital with chest infections.
Query!
Trial website
https://parrot-trial.org.uk/
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
95930
0
Prof Paul Stephen McNamara
Query!
Address
95930
0
Consultant in Paediatric Respiratory Medicine, Alder Hey Children’s NHS Foundation Trust
Professor of Child Health, University of Liverpool
Institute in The Park
Alder Hey Children’s Hospital
Eaton Road
Liverpool
L12 2AP
Query!
Country
95930
0
United Kingdom
Query!
Phone
95930
0
+44151 282 4531
Query!
Fax
95930
0
Query!
Email
95930
0
[email protected]
Query!
Contact person for public queries
Name
95931
0
Prof Paul Stephen McNamara
Query!
Address
95931
0
Consultant in Paediatric Respiratory Medicine, Alder Hey Children’s NHS Foundation Trust
Professor of Child Health, University of Liverpool
Institute in The Park
Alder Hey Children’s Hospital
Eaton Road
Liverpool
L12 2AP
Query!
Country
95931
0
United Kingdom
Query!
Phone
95931
0
+44151 794 9838
Query!
Fax
95931
0
Query!
Email
95931
0
[email protected]
Query!
Contact person for scientific queries
Name
95932
0
Prof Paul Stephen McNamara
Query!
Address
95932
0
Consultant in Paediatric Respiratory Medicine, Alder Hey Children’s NHS Foundation Trust
Professor of Child Health, University of Liverpool
Institute in The Park
Alder Hey Children’s Hospital
Eaton Road
Liverpool
L12 2AP
Query!
Country
95932
0
United Kingdom
Query!
Phone
95932
0
+44151 794 9838
Query!
Fax
95932
0
Query!
Email
95932
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Discussions at the University of Liverpool Clinical Trials Unit are currently ongoing regarding data sharing and how we are planning to share patient level data for all of our trials. This field will be updated once a decision has been made.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF